Eli Lilly issues press release on retatrutide Phase 3 obesity trial results

Eli Lilly and Company

Eli Lilly and Company

LLY

0.00
  • Eli Lilly posted a press release disclosing positive topline Phase 3 results for obesity drug candidate retatrutide in TRIUMPH-2, TRIUMPH-3.
  • TRIUMPH-2 showed up to 20.8% average weight loss at 80 weeks in adults with obesity or overweight, type 2 diabetes.
  • TRIUMPH-3 showed up to 22.6% average weight loss at 80 weeks in severe obesity with established cardiovascular disease.
  • FDA Biologics License Application filing targeted for Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eli Lilly and Company published the original content used to generate this news brief via PR Newswire (Ref. ID: 202607230645PR_NEWS_USPR_____DE10479) on July 23, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.